Navigation Links
Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants

LOS ANGELES, April 9, 2012 /PRNewswire/ -- Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company developing targeted cancer immunotherapies, announced today that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 

Oppenheimer & Co. Inc. and Roth Capital Partners, LLC are acting as joint book-running managers for the offering.  BTIG, LLC is acting as co-manager for the offering.

Genesis Biopharma intends to use the net proceeds of the offering to repay outstanding debt obligations, to fund research and development activities, and for general corporate purposes.

The securities described above are being offered by Genesis Biopharma pursuant to a shelf registration statement on Form S-3, including a base prospectus, previously filed with, and declared effective by, the Securities and Exchange Commission (SEC).  The securities may be offered only by means of a prospectus.  A preliminary prospectus supplement related to the offering has been filed with the SEC and will be available on the SEC's website located at Electronic copies of the preliminary prospectus supplement and the base prospectus relating to the offering may be obtained, when available, from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 300 Madison Avenue, 5th Floor, New York, NY, 10017, by telephone at (212) 667-8563, or via email at and from Roth Capital Partners, LLC, Equity Capital Markets, 888 San Clemente Drive, Newport Beach, CA 92660, by telephone at (800) 678-9147, or via email at  Before you invest, you should read the preliminary prospectus supplement and the base prospectus and other documents Genesis Biopharma has filed or will file with the SEC for more complete information about Genesis Biopharma and the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Genesis Biopharma, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is engaged in the development and commercialization of autologous cell therapies for the treatment of various cancers.  The company's lead product candidate, Contego™, is a ready-to-infuse autologous cell therapy utilizing tumor infiltrating lymphocytes for the treatment of patients with Stage IV metastatic melanoma.  Contego™ is based on a currently available physician-sponsored investigational therapy at the National Cancer Institute, MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute for the treatment of Stage IV metastatic melanoma. 

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the proposed public offering and the intended use of proceeds from the offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including market conditions, risks associated with the cash requirements of the company's business and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission, and represent the company's views only as of the date they are made and should not be relied upon as representing the company's views as of any subsequent date.  The company does not assume any obligation to update any forward-looking statements.

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ValGenesis Suite 2.5 Certified by SAP as Powered by SAP NetWeaver®
2. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
3. ThermoGenesis Announces Approval of AXP® by India Ministry of Health
4. ThermoGenesis Announces Acceptance of AXP® Submission by Regulatory Body in China
5. Genesis Biosciences Announces New Hire and Promotions on Operational and Scientific Staff
6. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2011 on September 12, 2011
7. Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies
8. Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors
9. Genesis Biopharma Names David Voyticky to Board of Directors
10. Genesis Biopharma Director William H. Andrews, Ph.D., Profiled in Popular Science Feature Story
11. Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board
Post Your Comments:
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
(Date:11/24/2015)... PHILADELPIA, PA (PRWEB) , ... November 24, 2015 , ... ... young entrepreneurs at competitive events in five states to develop and pitch their BIG ... student projects from each state are competing for votes to win the title of ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
Breaking Biology Technology:
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
(Date:10/29/2015)... JOLLA, Calif. , Oct. 29, 2015  The ... a new report titled, "DNA Synthesis and Biosecurity: Lessons ... well the Department of Health and Human Services guidance ... issued in 2010. --> ... but it also has the potential to pose unique ...
Breaking Biology News(10 mins):